Table 2 Cardiovascular characteristics of the AML study cohort (IDHwildtype vs. IDH1mutated or IDH2mutated vs. pooled IDH1mutated and IDH2mutated).
Unweighted cohort (total n = 363) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
AML total | IDH wildtype | IDH1 mutated | IDH2 mutated | IDH1/2 mutated | ||||||||
(Total n = 363) | a.d. (n/total n) | (Total n= 298) | a.d. (n/total n) | (Total n = 26) | a.d. (n/ total n) | (Total n = 39) | a.d. (n/total n) | p | (Total n = 65) | a.d. (n/total n) | p | |
CAD (%) | 7.5 | (24/321) | 6.4 | (17/265) | 26.1 | (6/23) | 3.0 | (1/33) | 0.002 | 12.5 | (7/56) | 0.116 |
Valvular disease (%) | 4.4 | (14/321) | 3.8 | (10/265) | 13.0 | (3/23) | 3.0 | (1/33) | 0.323 | 7.1 | (4/56) | 0.403 |
Heart failure (%) | 2.5 | (8/320) | 2.3 | (6/264) | 0.0 | (0/23) | 6.1 | (2/33) | 0.307 | 3.6 | (2/56) | 0.572 |
Cardiovascular risk factors (%) | 0.060 | 0.198 | ||||||||||
0–1 risk factors | 88.9 | (287/323) | 89.9 | (240/267) | 73.9 | (17/23) | 90.9 | (30/33) | 83.9 | (47/56) | ||
2–4 risk factors | 11.1 | (36/323) | 10.1 | (27/267) | 26.1 | (6/23) | 9.1 | (3/33) | 16.1 | (9/56) | ||
Sinusrhythm (%) | 91.8 | (292/318) | 92.0 | (242/263) | 90.9 | (20/22) | 90.9 | (30/33) | 0.964 | 90.9 | (50/55) | 0.785 |
Systolic blood pressure (mmHg) | 35.9 | (127/354) | (100/289) | (11/26) | (16/39) | 0.268 | (27/65) | 0.282 | ||||
Median | 130.0 | 120.0 | 130.0 | 125.0 | ||||||||
Range | 80.0–180.0 | 110.0–140.0 | 110.0–150.0 | 110.0–150.0 | ||||||||
Diastolic blood pressure (mmHg) | 35.3 | (125/354) | (98/289) | (11/26) | (16/39) | 0.884 | (27/65) | 0.791 | ||||
Median | 75.0 | 80.0 | 80.0 | 80.0 | ||||||||
Range | 40.0–105.0 | 60.0–90.0 | 65.0–90.0 | 60.0–90.0 | ||||||||
Heart rate (beats per min) | 49.9 | (181/363) | (150/298) | (14/26) | (17/39) | 0.427 | (31/65) | 0.825 | ||||
Median | 88.0 | 93.5 | 84.0 | 88.0 | ||||||||
Range | 60.0–152.0 | 62.0–122.0 | 66.0–118.0 | 62.0–120.0 | ||||||||
ACEi/ARB (%) | 18.9 | (60/317) | 17.6 | (46/262) | 26.1 | (6/23) | 25.0 | (8/32) | 0.395 | 25.5 | (14/55) | 0.174 |
ß-blocker (%) | 17.9 | (57/317) | 16.8 | (44/262) | 30.4 | (7/23) | 18.8 | (6/32) | 0.262 | 23.6 | (13/55) | 0.230 |
MR-antagonists (%) | 0.0 | (0/317) | 0.8 | (2/262) | 0.0 | (0/23) | 0.0 | (0/32) | 0.810 | 0.0 | (0/55) | 0.516 |
